GlassScriptPhysician profile
David P Wien
NPI 1912904038
$16,809.90
in general payments reported to CMS, 2019-2025
32 companies · $2,802 in 2025
The $2,802 reported for 2025 was more than what 79% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,363 · 2020: $2,729 · 2021: $1,481 · 2022: $2,023 · 2023: $2,702 · 2024: $2,710 · 2025: $2,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,039 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,038.77 |
| Education | $175.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,515.44 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $3,445.00 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $2,346.49 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,645.06 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $871.05 | 2021-2025 | Orladeyo |
| Csl Behring | $865.08 | 2019-2025 | Haegarda, Andembry, Kcentra |
| Genentech USA, INC. | $546.27 | 2019-2025 | Xolair |
| Pharming Healthcare, INC. | $466.88 | 2019-2025 | Ruconest |
| Amgen INC. | $451.10 | 2022-2025 | Tezspire |
| Optinose US, INC. | $412.43 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $283.68 | 2020-2025 | Glassia, Hyqvia, Takhzyro |
| Alk-Abello, INC | $278.26 | 2019-2023 | Standardized Mite D. Farinae, Odactra, Alternaria Tenuis |
| Novartis Pharmaceuticals Corporation | $200.96 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $164.60 | 2025 | Neffy |
| Grifols USA, LLC | $147.55 | 2024 | Xembify |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $141.14 | 2019 | |
| Abbvie INC. | $125.00 | 2023 | Rinvoq |
| Lilly USA, LLC | $124.99 | 2025 | Ebglyss |
| Sanofi-Aventis U.S. LLC | $121.36 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.01 | 2019 | |
| Horizon Therapeutics Plc | $92.71 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $89.72 | 2022-2023 | Airduo Digihaler |
| Aimmune Therapeutics, INC. | $66.02 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $61.26 | 2019-2023 | |
| Leo Pharma INC. | $57.77 | 2025 | Anzupgo, Adbry |
| Pfizer INC. | $57.26 | 2022-2024 | |
| Biocryst Pharmaceuticals, INC. | $33.83 | 2020 | |
| Hikma Pharmaceuticals USA | $32.36 | 2023 | Ryaltris |
| Paratek Pharmaceuticals, INC. | $21.88 | 2025 | Xhance |
| Ionis Pharmaceuticals, INC. | $21.17 | 2025 | Dawnzera |
| Mckesson Medical-Surgical, INC. | $15.00 | 2021 | |
| Sunovion Pharmaceuticals INC. | $13.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.